Insulin-like growth factor (IGF)-I and IGF-binding protein-3 serum levels in relapsing-remitting and secondary progressive multiple sclerosis patients

R. Lanzillo; C. Di Somma; M. Quarantelli; G. Ventrella; M. Gasperi; A. Prinster; G. Vacca; C. Pivonello; G. Orefice; A. Colao; V. B. Morra

doi:10.1111/j.1468-1331.2011.03433.x

Insulin-like growth factor (IGF)-I and IGF-binding protein-3 serum levels in relapsing-remitting and secondary progressive multiple sclerosis patients

R. Lanzillo, C. Di Somma, M. Quarantelli, G. Ventrella, M. Gasperi, A. Prinster, G. Vacca, C. Pivonello, G. Orefice, A. Colao, V. B. Morra

IRCCS SDN

Research output: Contribution to journal › Article

Abstract

Background: Insulin-like growth factor (IGF)-I has a role in remyelination, and insulin-like growth factor-binding protein-3 (IGFBP-3) might reduce its bioavailability. A role of IGFBP-3 in multiple sclerosis (MS) progression was hypothesized in patients with primary progressive (PP) MS. Objective: To evaluate serum levels of IGF-I and IGFBP-3 in patients with relapsing-remitting (RR) and secondary progressive (SP) MS and their correlations with disease activity and progression. Methods: Sixty-three (41 RR and 22 SP) 'naive' MS patients and 60 age-matched healthy controls were enrolled. Patients were assessed through clinical [Expanded Disability Status Scale (EDSS), Multiple Sclerosis Severity Scale (MSSS), number of relapses] and laboratory investigations. IGF-I and IGFBP-3 were measured by ELISA. Results: Levels of IGF-I and IGFBP-3 were similar in the two MS groups. IGFBP-3 levels were higher in patients with MS than in controls (P

Original language	English
Pages (from-to)	1402-1406
Number of pages	5
Journal	European Journal of Neurology
Volume	18
Issue number	12
DOIs	https://doi.org/10.1111/j.1468-1331.2011.03433.x
Publication status	Published - Dec 2011

Fingerprint

Keywords

Case-control study
Insulin-like growth factor-binding protein-3
Insulin-like growth factor-I
Multiple sclerosis
Relapsing-remitting
Secondary progressive

ASJC Scopus subject areas

Clinical Neurology
Neurology

Cite this

Lanzillo, R., Di Somma, C., Quarantelli, M., Ventrella, G., Gasperi, M., Prinster, A., Vacca, G., Pivonello, C., Orefice, G., Colao, A., & Morra, V. B. (2011). Insulin-like growth factor (IGF)-I and IGF-binding protein-3 serum levels in relapsing-remitting and secondary progressive multiple sclerosis patients. European Journal of Neurology, 18(12), 1402-1406. https://doi.org/10.1111/j.1468-1331.2011.03433.x

Insulin-like growth factor (IGF)-I and IGF-binding protein-3 serum levels in relapsing-remitting and secondary progressive multiple sclerosis patients. / Lanzillo, R.; Di Somma, C.; Quarantelli, M.; Ventrella, G.; Gasperi, M.; Prinster, A.; Vacca, G.; Pivonello, C.; Orefice, G.; Colao, A.; Morra, V. B.

In: European Journal of Neurology, Vol. 18, No. 12, 12.2011, p. 1402-1406.

Research output: Contribution to journal › Article

Lanzillo, R, Di Somma, C, Quarantelli, M, Ventrella, G, Gasperi, M, Prinster, A, Vacca, G, Pivonello, C, Orefice, G, Colao, A & Morra, VB 2011, 'Insulin-like growth factor (IGF)-I and IGF-binding protein-3 serum levels in relapsing-remitting and secondary progressive multiple sclerosis patients', European Journal of Neurology, vol. 18, no. 12, pp. 1402-1406. https://doi.org/10.1111/j.1468-1331.2011.03433.x

Lanzillo, R. ; Di Somma, C. ; Quarantelli, M. ; Ventrella, G. ; Gasperi, M. ; Prinster, A. ; Vacca, G. ; Pivonello, C. ; Orefice, G. ; Colao, A. ; Morra, V. B. / Insulin-like growth factor (IGF)-I and IGF-binding protein-3 serum levels in relapsing-remitting and secondary progressive multiple sclerosis patients. In: European Journal of Neurology. 2011 ; Vol. 18, No. 12. pp. 1402-1406.

@article{59a7af6da68a42099a8de0b21bc7cc82,

title = "Insulin-like growth factor (IGF)-I and IGF-binding protein-3 serum levels in relapsing-remitting and secondary progressive multiple sclerosis patients",

abstract = "Background: Insulin-like growth factor (IGF)-I has a role in remyelination, and insulin-like growth factor-binding protein-3 (IGFBP-3) might reduce its bioavailability. A role of IGFBP-3 in multiple sclerosis (MS) progression was hypothesized in patients with primary progressive (PP) MS. Objective: To evaluate serum levels of IGF-I and IGFBP-3 in patients with relapsing-remitting (RR) and secondary progressive (SP) MS and their correlations with disease activity and progression. Methods: Sixty-three (41 RR and 22 SP) 'naive' MS patients and 60 age-matched healthy controls were enrolled. Patients were assessed through clinical [Expanded Disability Status Scale (EDSS), Multiple Sclerosis Severity Scale (MSSS), number of relapses] and laboratory investigations. IGF-I and IGFBP-3 were measured by ELISA. Results: Levels of IGF-I and IGFBP-3 were similar in the two MS groups. IGFBP-3 levels were higher in patients with MS than in controls (P",

keywords = "Case-control study, Insulin-like growth factor-binding protein-3, Insulin-like growth factor-I, Multiple sclerosis, Relapsing-remitting, Secondary progressive",

author = "R. Lanzillo and {Di Somma}, C. and M. Quarantelli and G. Ventrella and M. Gasperi and A. Prinster and G. Vacca and C. Pivonello and G. Orefice and A. Colao and Morra, {V. B.}",

year = "2011",

month = dec

doi = "10.1111/j.1468-1331.2011.03433.x",

language = "English",

volume = "18",

pages = "1402--1406",

journal = "European Journal of Neurology",

issn = "1351-5101",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "12",

}

TY - JOUR

T1 - Insulin-like growth factor (IGF)-I and IGF-binding protein-3 serum levels in relapsing-remitting and secondary progressive multiple sclerosis patients

AU - Lanzillo, R.

AU - Di Somma, C.

AU - Quarantelli, M.

AU - Ventrella, G.

AU - Gasperi, M.

AU - Prinster, A.

AU - Vacca, G.

AU - Pivonello, C.

AU - Orefice, G.

AU - Colao, A.

AU - Morra, V. B.

PY - 2011/12

Y1 - 2011/12

N2 - Background: Insulin-like growth factor (IGF)-I has a role in remyelination, and insulin-like growth factor-binding protein-3 (IGFBP-3) might reduce its bioavailability. A role of IGFBP-3 in multiple sclerosis (MS) progression was hypothesized in patients with primary progressive (PP) MS. Objective: To evaluate serum levels of IGF-I and IGFBP-3 in patients with relapsing-remitting (RR) and secondary progressive (SP) MS and their correlations with disease activity and progression. Methods: Sixty-three (41 RR and 22 SP) 'naive' MS patients and 60 age-matched healthy controls were enrolled. Patients were assessed through clinical [Expanded Disability Status Scale (EDSS), Multiple Sclerosis Severity Scale (MSSS), number of relapses] and laboratory investigations. IGF-I and IGFBP-3 were measured by ELISA. Results: Levels of IGF-I and IGFBP-3 were similar in the two MS groups. IGFBP-3 levels were higher in patients with MS than in controls (P

AB - Background: Insulin-like growth factor (IGF)-I has a role in remyelination, and insulin-like growth factor-binding protein-3 (IGFBP-3) might reduce its bioavailability. A role of IGFBP-3 in multiple sclerosis (MS) progression was hypothesized in patients with primary progressive (PP) MS. Objective: To evaluate serum levels of IGF-I and IGFBP-3 in patients with relapsing-remitting (RR) and secondary progressive (SP) MS and their correlations with disease activity and progression. Methods: Sixty-three (41 RR and 22 SP) 'naive' MS patients and 60 age-matched healthy controls were enrolled. Patients were assessed through clinical [Expanded Disability Status Scale (EDSS), Multiple Sclerosis Severity Scale (MSSS), number of relapses] and laboratory investigations. IGF-I and IGFBP-3 were measured by ELISA. Results: Levels of IGF-I and IGFBP-3 were similar in the two MS groups. IGFBP-3 levels were higher in patients with MS than in controls (P

KW - Case-control study

KW - Insulin-like growth factor-binding protein-3

KW - Insulin-like growth factor-I

KW - Multiple sclerosis

KW - Relapsing-remitting

KW - Secondary progressive

UR - http://www.scopus.com/inward/record.url?scp=81855194365&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=81855194365&partnerID=8YFLogxK

U2 - 10.1111/j.1468-1331.2011.03433.x

DO - 10.1111/j.1468-1331.2011.03433.x

M3 - Article

C2 - 21585623

AN - SCOPUS:81855194365

VL - 18

SP - 1402

EP - 1406

JO - European Journal of Neurology

JF - European Journal of Neurology

SN - 1351-5101

IS - 12

ER -

Access to Document

10.1111/j.1468-1331.2011.03433.x